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ORIGINAL ARTICLE
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Jurfest Rivero Ceccon3
Newborns with staphylococcus aureus and 
coagulase-negative sepsis treated with 
vancomycin after an increase in serum levels 
around the valley
Abstract
Introduction: Vancomycin is a glycopeptide antibiotic considered 
the gold standard in the treatment of staphylococcal infections that 
are oxacillin-resistant. 
Objective: To analyse the concentration of serum level in the 
voucher (one hour before the next administration of the drug dose) 
of vancomycin in newborns with Staphylococcus aureus infection 
or oxacillin-resistant coagulase-negative. 
Methods: This is an experimental study with data collection 
between the years 2001 and 2016. We selected 30 patients who 
had staphylococcus aureus and coagulase-negative sepsis and 
used vancomycin as a treatment. We collected and recorded their 
serum levels. 
Results: Of the 30 patients included in the present study, 80% were 
preterm. Among all the newborns, mean serum concentrations in 
the vancomycin valley were 40% adequate, 13.34% lower than 
expected, and 46.67% higher than the reference values. In seven 
patients (23.34%), the first serum level in the Vancomycin valley 
collected was adequate, but in nine (30%) and 14 (46.67%) patients, 
the serum concentration in the valley was respectively below and 
above the correct values. After dose shifting of those who did not 
achieve adequate levels, only three of the 14 patients in whom the 
first dose was not adequate had a mean serum total level within 
the expected range; the remaining 11 stayed at high levels, which 
raised great concern due to the fact that if the infection is not being 
treated, the elevated serum level leads to nephrotoxic and ototoxic 
problems. The monitoring of serum levels in the vancomycin 
valley is of great importance as it minimises nephrotoxic effects, 
thus increasing the efficacy of the drug. The dosage adjustment 
of vancomycin in severely ill patients admitted to an intensive care 
unit is important and requires more studies related to this area, as 
the work of a multidisciplinary body makes the treatment better and 
more specific. 
Conclusion: The concentrations of serum levels in the Vancomycin 
valley (10–15 μg/mL) in patients hospitalised in a neonatal intensive 
care unit of a reference hospital in Latin America were thought to be 
bactericidal; however, this is not the values observed in our study.
Keywords: vancomycin, intensive care units, neonatal, newborn, 
staphylococcus aureus.
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Staphylococcus aureus and coagulase-negative 
staphylococci are the most common infections in both 
neonatal and paediatric intensive care units1,2 and have a 
significant impact on patients’ mortality and morbidity3-5. 
Penicillin-resistant staphylococci have emerged since 
the 1980s, and currently both types are sensitive to 
vancomycin only. For this reason, this drug has long been 
considered the gold standard in therapy against these 
infectious agents6.
The Food and Drug Administration (FDA) approved 
vancomycin for use in the United States in 1958 to treat 
penicillin-resistant1 Staphylococcus aureus infection. It is 
a complex, glycopeptide antibiotic containing amino acids 
and sugars and has high molecular2,3 weight with activity 
in the pH range between 6.0 and 8.0.  
 INTRODUCTION
 METHODS
Figure : Vancomycin structure.
Source: VILA et al., 2007.
Several situations require the monitoring of serum 
levels and adjustment of vancomycin doses. Clinical 
factors such as site and severity of infection, suspected 
or confirmed infectious agent, underlying disease and 
concomitant therapies7, and the fact that the drug has a 
narrow therapeutic range all increase the risk of side 
effects, such as nephritic syndrome and ototoxicity, skin 
reactions (e.g., erythema), and flushing histamine-like and 
other anaphylactic reactions, when anaesthetics are given. 
The association with aminoglycosides and furosemide that 
is frequent in the sepsis patient increases toxicity. Effects 
on neuromuscular blockade may be enhanced when non-
depolarizing muscle relaxants are administered.
There are important interindividual pharmacokinetic 
variations (age, weight, renal function) that emphasise the 
importance of drug monitoring and dosage adjustment 
in clinical practice8. However, even though vancomycin 
has been used for more than half a century in neonatal 
care, dosage and efficacy still currently demonstrate its 
pharmacological complexity.
Preterm infants are susceptible to higher 
concentrations of free and bioavailable drugs due to: 
decreased serum protein concentration; high fetal albumin 
concentration, which has decreased affinity for drug 
binding; low plasma pH; which reduces protein binding 
to acidic drugs; and serum concentration of competing 
molecules at the binding of drugs with proteins, such 
as bilirubin and free fatty acids. Thus, a standard dose 
becomes an exaggerated dose and causes toxic effects. 
On the other hand, the greater volume of drug distribution 
to tissues leads to a greater need to concentrate drugs per 
kilo of body weight in order to maintain adequate serum 
concentration, since protein-free drugs are also more 
available to be metabolised and excreted9. 
The therapeutic values for use of vancomycin, 
according to Neofax® (dosage book used in most Neonatal 
Units) up to 2009, were 5–10 μg/ml for valley concentrations 
(4 to 8 times minimum inhibitory concentration (MIC) 
and 20–40 μg/ml for peak concentrations (10 to 30 MIC) 
at doses of 10–15 mg/kg10. Currently, neonatal referrals 
recommend higher serum concentrations in the valley of 
10–15 μg/ml, but doses remain unchanged11,12.
Thus, the objective is to analyse the concentration 
of serum levels in the voucher (one hour before the 
next administration of the drug dose) of vancomycin in 
newborns admitted to a neonatal intensive care unit with 
Staphylococcus aureus or coagulase-negative oxacillin-
resistant strains are adequate and according to the 
literature.
This is a retrospective descriptive and interventional 
study, made when the levels of the drug were outside the 
range of normal, performed at the Center for Neonatal 
Intensive Care (CTNI-2) of the Children’s Institute of 
the Hospital das Clínicas of the University of São Paulo, 
which has 20 beds for newborns hospitalised in serious 
condition with both clinical and surgical diseases that 
require specialised care for more than 24 hours.
Voucher is defined as the time period of one hour 
before the next administration of the dose of the drug. The 
choice of voucher was given by being routinely dosed to 
indicate the levels/values of the adequate dosage of the 
drug in the therapeutic treatment of the newborns until the 
end of the drug Activity.
Inclusion criteria 
We obtained a list of patients who, according to the 
registry of the unit and the hospital, were admitted to the 
neonatal ICU of the Children’s Institute and had a diagnosis 
of sepsis by Staphylococcus aureus and/or coagulase-
negative. From this list, we randomised newborns (under 
the age of one year) that were hospitalised between 2001 
and 2016 and of life was done. We obtained data collected 
at the time of administration of vancomycin (i.e., weight, 
age, gestational age, administered doses of vancomycin, 
and serum levels) from the medical records of patients 
with bloodstream infection by Staphylococcus aureus 
and coagulase-negative using vancomycin as a form of 
treatment.
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level in the vancomycin vial (i.e., above or below the 
reference value of 10–15 μg/ml), the time interval of drug 
administration was modified. 
The vancomycin voucher as quoted in the 
introduction is one hour before the next administration of 
the drug and represents the efficacy thereof, which must 
still be between the desired values (i.e., it would still be 
acting even at the end of the time before the next dose. 
Data collected from serum levels were statistically 
analysed using means, medians, standard deviations, and 
% mean deviation. The present study was approved by 
the Research and Ethics Committee of the Department of 




We excluded patients whose medical records had 
no serum level registry in the vancomycin voucher or 
who did not receive it as a form of treatment. All patients 
who had serum levels in the vancomycin valley below, 
adequate, or above the reference values were included, 
even though the admission period of these patients had 
different serum levels of reference. 
The prescription of vancomycin was made 
according to the literature followed, Neofax®, which 
suggests doses according to the weight and gestational 
age of the newborn. The suggested doses are 10–15 mg/
kg with intervals of administration followed empirically; 
thus, they could be 6/6 hours, 8/8 hours, 12/12 hours, 
18/18 hours, up to 24/24 hours, depending on the serum 
Table 1: Demographic data of the 30 patients studied. Brazil, 2018
Case Year Age Age when administered 
vancomycin
Gestacional age Weigth Sex
1 2001 14 days 17  days 41 weeks 2515 g M
2 2004 9  days 21  days 29  weeks 1120 g M
3 2005 1  day 20  days 28  weeks 1130 g M
4 2005 1  day 9  days 28  weeks 1220 g F
5 2005 16  days 20  days 39  weeks 3200 g M
6 2006 25  days 28  days 36  weeks 2420 g F
7 2006 9  days 20  days 40  weeks 3300 g F
8 2006 1  day 8   days 28  weeks 690 g F
9 2007 26  days 37  days 40  weeks 3780 g M
10 2007 1  day 10  days 31  weeks 1590g M
11 2007 30  days 34  days 31  weeks 1450 g F
12 2007 10  days 10  days 33  weeks 1085 g F
13 2007 1  day 4  days 28  weeks 635 g M
14 2008 5  days 10  days 32  weeks 1430 g M
15 2008 19  days 24  days 36  weeks 3300 g F
16 2008 8  days 12  days 35  weeks 2300 g F
17 2009 51  days 61  days 35  weeks 3710 g M
18 2009 1  day 9  days 34  weeks 1120 g F
19 2009 25  days 23  days 33  weeks 960 g M
20 2009 8  days 8  days 35  weeks 1935 g F
21 2009 65  days 67  days 35  weeks 1620 g M
22 2012 2  days 7  days 41  weeks 3675 g M
23 2013 22  days 22  days 31  weeks 935 g F
24 2013 1  day 36  days 37  weeks 2882 g M
25 2015 56  days 57  days 31  weeks 1125 g M
26 2016 29  days 32  days 33  weeks 1600 g F
27 2016 4  days 8  days 34  weeks 1925 g F
28 2016 19  days 24  days 25  weeks 810g F
29 2016 1  day 8  days 32  weeks 1050 g M
30 2016 1  day 12  days 35  weeks 2300 g M
M; male, F; female
Thirty newborns (13 females, 43.4%) were 
included, of which 24 (80%) were premature. The mean 
age at which vancomycin treatment was started was 21.94 
days. Through the records of laboratory tests performed, 
blood cultures were positive for Staphylococcus aureus 
in 12 patients and blood culture positive for S. coagulase-
negative 18 newborns (Table 1 and Table 2). Of the 30 
newborns, 12 (40%) had adequate mean serum levels, but 
four (13.34%) had mean values below that expected and 14 
(46.67%) had means above the reference values (Table 3).
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Table 2: Laboratory tests and diagnosis of the 30 patients studied. Brazil, 2018
Case Laboratory exams Diagnosis Sepse provein
1 HMC + for S Aeureus RNT AIG
2 HMC + for S aureus RNPT MBP AIG
3 HMC + and catheter tip for S. coagulase negative RNPT MBP AIG
4 HMC + for S coagulase negative RNPT MBP AIG
5 HMC - for S coagulase negative RNT AIG
6 HMC - for S coagulase negative RNPT BP .AIG
7 HMC + for S. Aureus RNT AIG
8 HMC + for S coagulase negative RNPT MMBP PIG
9 HMC + and catheter tip for S. coagulase negative RNT GIG
10 HMC + and catheter tip for S. aureus RNPT BP AIG
11 HMC + for S coagulase negative RNPT MBP AIG
12 HMC + for S coagulase negative RNPT MBP PIG
13 HMC + for S coagulase negative RNPT MMBP PIG
14 HMC and catheter tip for S coagulase negative RNPT MBP AIG
15 Culture of ocular secretion + para S aureus and HMC +  for S aureus RNPT GIG
16 HMC + for S. Aureus RNPT BP .AIG
17 HMC + for S aureus e Enterococcus faecalis RNPT GIG
18 HMC + for S. Aureus RNPT MPB PIG
19 HMC + for S coagulase negative RNPT MMBP PIG
20 HMC + for S. coagulase negative RNPT BP .AIG
21 HMC + for S. aureus e Enterococcus faecalis RNPT BP .AIG
22 HMC + for S. coagulase negative RNT AIG
23 HMC + for S coagulase negative RNPT MMBP PIG
24 HMC + for S. coagulase negative RNT AIG
25 HMC + for S. coagulase negative RNPT MBP AIG
26 HMC + for S. Aureus RNPT BP .AIG
27 HMC + for S. Aureus RNPT BP .AIG
28 HMC + for S coagulase negative RNPT MMBP AIG
29 HMC + and catheter tip for S. Aureus RNPT MBP PIG
30 HMC + for S coagulase negative RNPT BP AIG
HMC - - hemocukura positive; RNT • term new born; R.XPT –pre-term new born; AÍG – adequate for gestational age:
PIG - small for gestational age; GIG - big for gestational age; BP - Low weight; MBP - very low weight; MMPB - very very low weight
Table 3: Serum levels in the vancomycin voucher of the 30 patients studied
Case Year SL vancomycin voucher
Average of SL 
voucher Median
Minimal values 
of SL in voucher
Maximum values 
of SL in voucher
Standard 
deviation
1 2001 9,6 9,6 9,6 9,6 9,6
2 2004 4,17,1 5,6 5,6 4,1 7,1






11,3 10 2,4 22,7






13,4 10 2,5 31,2





6,1 4,76 4,5 9,05
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10,17 7,46 7,9 14,4















9,1 9,7 4 13,7
15 2008 7,5 7,5 7,5 7,5 7,5
16 2008 12,92,2 7,6 7,6 2,2 12,9
17 2009 10 10 10 10 10



















8 7,8 6,4 9,5







14,4 12,9 9,4 23,9










20,7 11,9 5,4 73,1
26 2016 17,111,2 14,2 14,2 11,2 17,1
27 2016 8,1 8,1 8,1 8,1 8,1
28 2016 25,5 25,5 25,5 25,5 25,5
29 2016 20,7 20,7 20,7 20,7 20,7
30 2016 3,6 3,6 3,6 3,6 3,6
Case Year SL vancomycin voucher
Average of SL 
voucher Median
Minimal values 
of SL in voucher
Maximum values 
of SL in voucher
Standard 
deviation
continuation: Table 3: Serum levels in the vancomycin voucher of the 30 patients studied
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 DISCUSSION
After 72 hours, the 30 newborns had serum levels 
in the vancomycin vouchers reassessed. Among them, 
seven (23.34%) had an adequate serum level, and nine 
(30%) and 14 (46.67%) had serum levels below and above 
the literature reference values, respectively. Thus, there 
was a change in dose and/or dosing interval prescribed for 
newborns that had lower- and higher-than-expected serum 
levels, collecting a second serum level after three days. 
It can be verified that of those who had the first serum 
level in the appropriate vancomycin valley (23.34%) and 
below (30%) of the reference, 13.24% of the patients 
in both cases had a total mean serum level adequately 
collected with a correct dosage adjustment. However, the 
14 patients who had a high score at the first serum level 
collection in the valley and had their doses of vancomycin 
modified. It was observed that the mean of all serum levels 
of 11 of these patients (36.67%) remained high and only 
three (10%) were adequate. 
Only 11 patients (36.67%) had the first serum level 
in the registered vancomycin voucher. Among them, three 
(10%) were below the reference values and four (13.34%) 
were at adequate levels as the same amount of patients 
with the high levels (Graph 1).
The analysis of the serum levels in the vancomycin 
valley showed that 60% of the patients were outside 
the proposed targets, of which 13.64% were below the 
expected level and 46.36% were above reference values. 
Serum levels below therapeutic levels are of great concern 
because there is a delay in the treatment of the infection as 
well as a greater susceptibility to resistance of the bacteria, 
forcing the clinician to increase the dosage empirically. 
Elevated serum levels are also of concern, as they can lead 
to nephrotoxic and ototoxic problems.
It is noteworthy that the meeting of these increased 
and low levels, since they are empirically adjusted and for 
a preterm NB a high dose of Vancomycin can cause renal 
failure. The waiting procedure for the dose in the valley is 
adequate and promotes evolution of the infection picture 
of the newborn.
Another issue of difficult therapeutic management 
is reaching therapeutic levels in neonates with renal 
dysfunction, due to the fact that glomerular filtration is 
responsible for the excretion of vancomycin and also for 
tubular functions in neonates still immature13,14. Of the 30 
newborns, 25% had elevated serum levels and presented 
renal problems treated with furosemide to improve 
renal function. In a situation such as this, the half-life 
of vancomycin may increase from 150–250 hours and 
provide an increase in the serum concentration of the drug 
and risk of toxicity, culminating in clinical worsening of 
the newborn15. Dialysis is the gold standard for the reversal 
of the clinical condition of the newborn and clearance and 
elimination of vancomycin.
However, in 2007 alone, there were guidelines 
published through the Infectious Diseases Society of 
America, along with other professional organisations, with 
multidisciplinary guidance on this program16. However, as 
far as the neonatal area is concerned, data are lacking on 
the consequences of these programs17.
In the neonatal intensive care unit (ICU), there is 
routine and frequent use of vancomycin. Sánches et al.18 
point out that vancomycin is used empirically in ICUs, 
making its use inappropriate. In the 1980s, antimicrobial 
management programs were introduced with the aim of 
reducing unnecessary therapies. 
It is worth mentioning that the use of vancomycin 
is very frequent also due to the scarcity of new antibiotics 
Graph 1: Average serum levels in the Vancomycin valley of studied patients. 12 RN (40%) appropriate levels 
4 (13.34%) level below expected and 14 (46.67) The average serum levels gave above the reference values
Average of sérum 
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 CONCLUSION
in the market. The discovery of new antibiotics faces a 
number of challenges that make research and development 
very difficult when compared to other types of medicine19. 
Pharmaceutical industries choose not to invest in the 
development of new antibiotics because their effectiveness 
only lasts for around two years due to indiscriminate use 
by the general population and by health professionals. 
Since vancomycin has been in use for more than 50 years, 
it must be used correctly and carefully.
Although there are modifications in the structure 
of vancomycin, from the introduction of quaternary 
ammonium salt at the C-terminal generating a second 
mechanism of action, resulting in better permeability of 
the drug in the cell wall, as well as being complementary 
in the inhibition of glycopeptide synthesis of the wall 
bacterial cell growth, with improvement in its therapeutic 
effects and reduction of the bacterial resistance event20, the 
valley dosage seems to be more adequate for the clinical 
conduction of the newborns, especially to avoid the 
toxicity produced by the drug. 
In addition, vancomycin is a glycopeptide 
antibiotic used to treat infections caused by gram-
positive micro-organisms. In monitoring the dosages 
of vancomycin, it is possible to obtain adequate and 
efficient serum concentrations for the treatment of 
infections. It is noteworthy that there is controversy in the 
therapeutic management of newborns with gram-positive 
micro-organisms, especially in the determination and 
interpretation of their serum concentrations. Measurement 
of serum vancomycin levels (vancocinemia) may aid in 
the prevention of toxicity and in the adequate maintenance 
of therapeutic serum concentration, avoiding low tissue 
penetration and failure to eliminate the outbreak of 
infection. 
Monitoring is based on the fact that the 
therapeutic response depends on the concentration 
of the drug in the patient’s bloodstream and not on 
the dose administered. The use of regular doses at 
periodic intervals does not mean constant levels in all 
patients due to differences in absorption, metabolism, 
excretion, and bioavailability of the drug administered 
that influence the definitive therapeutic effect. Thus, 
the monitoring of serum concentrations both in the 
peak and in the vancomycin voucher is essential to 
assess the toxicity or suitability of the medicine used 
in the clinic of the critically ill neonate. 
In the majority of neonates hospitalised in the 
Unit of Neonatal Intensive Care of the Reference 
Hospital of Latin America, there was a rate of serum 
level in the valley raised to the expected standards, 
causing greater toxic injury. It is clear that the 
metabolism of each drug depends on the stage of 
disease in the patient; however, with vancomycin, it is 
very difficult because the concentration of the drug in 
the body exceeds the therapeutic range, reaching the 
toxic dose and often worsening the condition of the 
newborn. Furthermore, vancomycin is widely used in 
neonatal intensive care patients who are afflicted with 
Staphylococcus aureus and coagulase-negative.
 The mean values observed in graph 1 show 
that of the 30 patients analysed, 12 (40%) had adequate 
serum levels in the valley between the red and green 
lines (10–15 μg/mL). In four newborns (13.4%), the 
mean level was below the expected level (below the 
red line, <10 μg/mL), and 14 newborns had above-
adequate serum levels (above the green line, >15 μg/
mL).
The monitoring of serum levels in the vancomycin 
valley is of great importance and should be performed in 
all hospitals because sepsis has become a major public 
health problem as the leading cause of death of newborns 
worldwide. We need more studies related to this area as 
well as the work of a multidisciplinary body that would 
both improve and specialise treatment.
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Resumo
Introdução: A vancomicina é um antibiótico glicopeptídico considerado padrão-ouro no tratamento de 
infecções por estafilococos resistentes à oxacilina. 
Objetivo: Analisar a concentração do nível sérico no vale (uma hora antes da próxima administração da 
dose do medicamento) de vancomicina em recém-nascidos com infecção por Staphylococcus aureus 
ou coagulase- negativa resistente à  Oxacilina.
Método: Trata-se de estudo experimental e com coleta de dados entre os anos de 2001 e 2016. Foram 
selecionados randomicamente 30 pacientes que tinham como diagnóstico sepse por Staphylococcus 
aureus e coagulase-negativa e fizeram uso da vancomicina como forma de tratamento e tiveram seus 
níveis séricos coletados e registrados nos prontuários. 
Resultados: Dos 30 pacientes incluídos no presente estudo, 80% eram pré-termos. Dentre todos 
os recém-nascidos as médias das concentrações séricas no vale da vancomicina foram de 40% 
adequadas, 13,34% abaixo do esperado e 46,67% acima dos valores de referência. Em 7 µpacientes 
(23,34%) o primeiro nível sérico no vale da vancomicina coletado foram adequados, porém em 9 (30%) 
e 14 (46,67%) a concentração sérica no vale foi, respectivamente, abaixo e acima dos valores corretos. 
Após a mudança de dose daqueles que não obtiveram níveis adequados, apenas 3 dos 14 pacientes 
em que a primeira dose não fora adequada tiveram uma média de nível sérico total dentro do esperado, 
enquanto os 11 restantes permaneceram com níveis elevados, os quais causam grandes preocupações 
devido ao fato de além de não estar sendo tratada a infecção, o nível sérico elevado acarreta em 
problemas nefrotóxicos e ototóxicos. O monitoramento dos níveis séricos no vale da vancomicina 
é de grande importância, pois minimiza os efeitos nefrotóxicos, assim aumentando a eficácia do 
medicamento. O ajuste posológico da vancomicina em pacientes em estado grave internados em uma 
Unidade de Terapia Intensiva é importante e necessita de mais estudos referentes à essa área, assim 
como o trabalho de um corpo multidisciplinar torna o tratamento melhor e mais específico.
Conclusão: As concentrações dos níveis séricos no vale de vancomicina em pacientes internados em 
Unidade de cuidados intensivos neonatais de Hospital de Referencia da América Latina entre 10 e 15 
µg/mL para serem bactericidas no entanto não é o que observamos nesta pesquisa.
Palavras-chave: vancomicina, monitorização terapêutica, níveis séricos no vale, unidade de terapia 
intensiva neonatal, recém-nascidos, Staphylococcus aureus.
